Therapeutic strategies targeting Cer metabolism are explored, including neutral sphingomyelinase inhibitors for hypertension, dietary DHA/EPA supplementation for dyslipidemia and the pharmacological approach of the anti-diabetic, metformin. The gene discussed is SMPD2; the disease is metabolic syndrome.